24 results about "Artemisinin" patented technology

The invention discloses an artemisinin extraction intelligent tracking and identification method, and relates to the technical field of image data processing. According to the method, an integrated closed-loop system is constructed through cooperation of four core technical means: based on classified filtering of foam stability difference and bimodal adaptive segmentation, dynamic foam is accurately removed, and preliminary interface extraction is optimized; the attention enhancement U-Net network is embedded into a channel attention module and an edge enhancement branch to realize accurate positioning and fluctuation tracking of a layered interface; the attention mechanism dynamically adjusts the bimodal weight, and completes multi-index cooperative tracking in combination with a partitioning strategy and an improved network; a crystal growth model is introduced to correct particle weight, a tracking effect is optimized by adopting layered resampling, and a closed-loop feedback mechanism of a crystal state and process parameters is established. All technical means are deeply coordinated, intelligent and accurate management and control of the whole extraction process are achieved, and reliable technical support is provided for artemisinin extraction production.

This invention discloses an acaricide targeting calcium ion channels and its application, belonging to the field of pesticides. Specifically, it relates to an acaricide based on the L-type calcium ion channel (L-VGCC) target and its application in the control of agricultural mites. The acaricide, artemisinin [Formula (I)], is a natural coumarin compound that is highly effective against agricultural mites and safe against predatory mites. It is a targeted, natural, and environmentally friendly acaricide with minimal harm to humans and the environment, and has the potential to be developed into a selective acaricide.

The invention discloses a chiral amino alcohol modified artemisinin derivative as well as a preparation method and application thereof, and belongs to the technical field of medicinal chemistry. According to the present invention, the alkali is adopted as the catalyst, the esterification reaction of the artesunate and the chiral amino alcohol is achieved for the first time, a series of the brand new derivatives simultaneously containing the artemisinin structure unit and the chiral amino alcohol structure unit are constructed, the synthesis path of the artemisinin derivative is expanded, and the research blank in the field is filled. The preparation method is novel, simple to operate, free of complex equipment, mild in reaction condition, high in reaction rate and high in yield, provides a new candidate compound for developing efficient and low-toxicity antitumor drugs, and has important clinical application value and market prospect.

The invention belongs to the technical field of biological medicine, and particularly relates to a rheumatism immune disease treatment composition combining traditional Chinese medicine active ingredients and immune regulation and application of the rheumatism immune disease treatment composition, and the rheumatism immune disease treatment composition comprises the following components in parts by weight: 10-50 parts of a traditional Chinese medicine active ingredient compound; 0.01 to 1 part of an immune regulation factor; 50 to 90 parts of pharmaceutic adjuvants; wherein the traditional Chinese medicine active component compound is prepared from the following components: astragaloside, artemisinin, curcumin and triptolide in a weight ratio of (2-5): (1-3): (1-4): (0.5-2); the immunoregulation factor is composed of recombinant human interleukin-10 (rhIL-10), a transforming growth factor-beta1 (TGF-beta1) and a CTLA4-Ig fusion protein according to a weight ratio of (1-3): (0.5-2): (1-4). The active ingredients of the traditional Chinese medicine cover a plurality of links of anti-inflammation, anti-oxidation, immunoregulation and the like, and immunoregulatory factors accurately intervene in immune cell activation and a cell factor network to jointly inhibit abnormal immune response.

The present invention provides an antimalarial composition comprising arjunetin and artemisinin. The composition exhibits synergistic antimalarial effect against malaria causing Plasmodium species including Plamsodium falciparum, P berghe species. The composition comprising Arjunetin and Artemisinin demonstrated potent antimalarial activity in vivo and in vitro with better survival and low parasite burden in the blood.

The invention discloses a novel oil-soluble micelle preparation. The component A comprises lecithin, soya bean lecithin, egg yolk lecithin, 1-palmitoyl-2-oleoyl lecithin, phosphatidylserine, phosphatidylinositol, phosphatidyl glycerol, cardiolipin, cephalin and dipalmitoyl phosphatidylcholine, and the component B comprises lecithin, soya bean lecithin, egg yolk lecithin, 1-palmitoyl-2-oleoyl lecithin, phosphatidylserine, phosphatidylinositol, phosphatidyl glycerol, phosphatidylcholine, cephalin and dipalmitoyl phosphatidylcholine; one or more of dipalmitoyl phosphatidyl ethanolamine and dipalmitoyl phosphatidyl ethanolamine; the component B comprises a component B1 and a component B2, and the component B1 comprises one or more of phytosterol, cholesterol, ergosterol, protopanoxadiol, protopanaxatriol, ganoderic acid, phytol, isophytol, retinol, andrographolide, paclitaxel, artemisinin and bisabolol; and the component B2 is prepared from one or more of 1, 2-hexanediol, ethylhexylglycerin, cyclohexyl glycerin, absolute ethyl alcohol and isosorbide dimethyl ether. The key point of the invention is to provide a low-cost formula and a low-cost preparation method for preparing the oil-soluble micelle preparation.

A method for extracting artemisinin, relating to the field of artemisinin extraction technology, includes the steps of extraction, enhanced extraction, separation, concentration, and purification. The purification employs an innovative column chromatography method, specifically a column height-to-diameter ratio of 1.2:1; adding hexane and diethyl ether eluent at a volume ratio of 8:2, with the added packing material height being 1.20-1.25 times the column diameter; and obtaining artemisinin after column chromatography. Alternatively, the innovative recrystallization method involves dissolving a paste in a crystallization vessel containing 50°C hot methanol, then lowering the temperature to 9-11°C, while locally heating and maintaining the temperature at the bottom of the crystallization vessel during cooling. Solid crystallization occurs under a uniform temperature distribution within the vessel, followed by filtration. This process is repeated twice to obtain artemisinin. The beneficial effects include an increased theoretical plate number of the chromatography column, significantly improved separation efficiency, and a significantly higher purity of artemisinin; the uniform temperature distribution within the crystallization vessel effectively improves the purity of the crystals.

The invention relates to the technical field of medicine, and discloses an artemisinin external patch for repairing wounds of scalds and burns and a preparation method and application thereof.The patch comprises a backing layer, medicine storage liquid and an anti-sticking layer, the backing layer is coated with the medicine storage liquid, and the medicine storage liquid is prepared from, by mass, 0.5%-2.0% of artemisinin, 8%-15% of solubilizer, 3%-10% of matrix material, 1%-3% of anti-sticking layer and the balance water. 1-5% of a transdermal enhancer, 0.1-0.5% of a stabilizer, 0.5-2.0% of a pH regulator, 0.1-0.5% of a preservative, 5-10% of a humectant and the balance of purified water. According to the patch, reactive oxygen species (ROS) is removed through a peroxide bridge structure of artemisinin, key signal channels such as NF-kappa B and TGF-beta are cooperatively regulated and controlled, and the multiple effects of resisting inflammation, resisting oxidation, resisting bacteria, promoting repair and resisting scars are achieved. Experiments prove that the composition can significantly accelerate wound healing and inhibit inflammation, oxidative injury and scar formation, solves the problems of short action time, low transdermal efficiency and single function of a traditional external product, and provides a multi-mechanism synergistic, safe, convenient and innovative external composition for treatment of scalds and burns.

The present application provides a plant expression vector, a recombinant transformant, artemisia and its application for increasing the content of artemisinin in artemisia. The first aspect of the present application provides a plant expression vector, wherein the plant expression vector comprises a gene encoding a transcription factor AabHLH39, and the gene encoding the transcription factor AabHLH39 has a nucleotide sequence as shown in SEQ ID NO: 1. The present application constructs a plant expression vector comprising a gene encoding a transcription factor AabHLH39, and transforms the artemisia, so that the artemisia overexpresses the transcription factor AabHLH39, thereby increasing the content of artemisinin in the artemisia.

The invention discloses an artemisinin compound containing a 10-bit ether side chain or a pharmaceutical salt thereof, the structural general formula is one of the following structures: the artemisinin compound containing the 10-bit ether side chain provided by the invention has a relatively obvious proliferation inhibition effect on liver cancer HepG2, lung cancer A549, intestinal cancer HCT116, hematologic tumors MV-4-11 and HL-60; the anti-tumor activity of part of the compounds is higher than that of commercially available drugs SAHA and belinostat, and the compounds are expected to be developed into novel anti-tumor drugs. In addition, the performance of a plurality of compounds is superior to the in-vitro antimalarial activity of artemisinin, and the compounds are expected to be developed into novel antimalarial drugs.

The invention belongs to the technical field of biological medicine, and discloses a method for analyzing an action target of artemisinin for treating renal clear cell carcinoma based on network pharmacology and a molecular docking technology, and the method comprises the following steps: S1, screening the action target of an artemisinin active component; s2, identifying candidate disease targets; s3, acquiring an intersection target point; s4, constructing a protein-protein interaction network and performing network topology analysis; s5, core target biological function and molecular action signal path analysis and visualization; s6, constructing an artemisinin-renal clear cell carcinoma-target spot-pathway network diagram; s7, exploring an action mechanism of artemisinin for improving the renal clear cell carcinoma based on a molecular docking technology; s8, carrying out survival analysis on the core target spot based on the TCGA database, and drawing a Kaplan-Meier curve; and S9, observing the influence of artemisinin and derivatives thereof on the activity of renal clear cell carcinoma 786-O cells by adopting a CCK-8 method. Network pharmacology and molecular docking technologies are applied, multiple omics data are integrated from the perspective of system biology, a drug-target-disease network is constructed, the interaction between artemisinin and renal clear cell carcinoma related targets is deeply analyzed, and the action mechanism of artemisinin on the aspects of genes, proteins, signal channels and the like is comprehensively revealed.

The invention relates to the technical field of biological medicine preparations, in particular to a recessive infected toxoplasma gondii repellent and a preparation method thereof, and the preparation method comprises the following steps: S1, sieving all the components; s2, mixing the artemisinin extract with a prepared carrier to prepare a premix A; s3, mixing the garlic extract with the turmeric extract to prepare a premix B; s4, dissolving vitamin C, zinc gluconate and sodium selenite in purified water to prepare a solution C; s5, mixing the premix A, the premix B and the solution C to form a main mixture D; s6, adding probiotic powder and a flavoring agent into the main mixture D to obtain a final mixture E; and S7, drying, granulating and forming to obtain a finished product of the repellent. According to the invention, through the synergistic combination of various plant extracts, micronutrients and probiotics and a low-temperature step-by-step preparation process, the efficient expelling of the recessive infected toxoplasma gondii and the stable regulation of the host immune environment are realized.

The application discloses an intelligent tracking and identification method for artemisinin extraction, and relates to the technical field of image data processing; the method cooperatively constructs an integrated closed-loop system through four core technical means: type filtering and bimodal adaptive segmentation based on foam stability difference, accurate removal of dynamic foam and optimization of preliminary interface extraction; attention-enhanced U-Net network embedding channel attention module and edge-enhanced branch, realizing accurate positioning and fluctuation tracking of layered interfaces; attention mechanism dynamically adjusts bimodal weight, combined with partition strategy and improved network to complete multi-index collaborative tracking; the crystallization growth model is introduced to correct particle weight, hierarchical resampling is adopted to optimize tracking effect, and a closed-loop feedback mechanism of crystallization state and process parameters is established. Deep cooperation of each technical means realizes intelligent and accurate control of the whole extraction process, and provides reliable technical support for artemisinin extraction production.

The invention relates to the technical field of microbial fermentation and biological medicine, in particular to a halogenated cyclopentenone compound as well as a preparation method and application thereof. The invention provides a halogenated cyclopentenone compound, which is obtained by carrying out fermentation culture, extraction and separation on mangrove forest plant artemisinin endophytic fungi Perconia macrospinosa F35, and the chemical structure of the halogenated cyclopentenone compound is identified by modern spectrum technologies such as nuclear magnetic resonance, high-resolution mass spectrum, ultraviolet spectrum and the like. Activity research shows that the series of halogenated cyclopentenone can effectively inhibit the activity of key virulence factor tyrosine phosphatase MptpA and MptpB of mycobacterium tuberculosis, shows good anti-tuberculosis activity by inhibiting pathogenic signal channels of pathogenic bacteria, and has wide application potential and development value in the field of anti-tuberculosis drugs.

The invention relates to application of rupestonic acid in preparation of drugs for treating non-alcoholic fatty liver disease, including non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. In a high fat diet induced non-alcoholic fatty liver model, rupestonic acid can significantly reduce the levels of aspartate aminotransferase, alanine aminotransferase, triglyceride and total cholesterol in mouse serum, and effectively improve liver fatty degeneration and lipid droplet accumulation. In a non-alcoholic steatohepatitis model induced by methionine-choline deficiency diet, rupestonic acid can significantly reduce the levels of serum aspartate aminotransferase and alanine aminotransferase, and effectively improve the fatty degeneration, inflammatory infiltration and fibrosis degree of the liver. The results fully show that the rupestonic acid disclosed by the invention provides a solid foundation for the definite treatment effect on the non-alcoholic fatty liver disease.

Despite recent efforts to eradicate malaria worldwide, this parasitic disease is still considered a major public health problem, with a total of 219 million malaria cases and 435,000 deaths in 2017 After a decade of use, however, resistance to CQ has emerged in some locations, including Southeast Asia, South America, and the Western Pacific region, spreading progressively into malaria-endemic areas, including Africa, where increases in malaria mortality have been observed. This has led, in recent years, to the adoption of artemisinin-based combination therapies. Artemisinin-based combination therapies remain effective in most parts of the world, but recent cases of resistance in Southeast Asia call for new approaches and especially new drugs to treat malaria. Thus, the present invention features CQ analogues of Formula (I) that exhibited high activity against CQ-sensitive and CQ-resistant blood parasites and were also active in mice. The present invention also provides pharmaceutical compositions comprising the compounds of Formula (I), use of said compounds, and methods for treating conditions caused by blood parasites.

The invention provides a transcription factor PfAP2-O5 inhibitor for Plasmodium falciparum, a pharmaceutical composition, and a drug for treating malaria resistant to artemisinin and an analog thereof. Disclosed in the present invention is new use of a triazoloquinoline derivative or a pharmaceutically acceptable salt or hydrate thereof. The triazoloquinoline derivative can inhibit the expression of an invasion gene pfap2-o5, block the invasion of Plasmodium falciparum into red blood cells, affect its growth and development, and achieve the effect of killing Plasmodium falciparum. Therefore, the triazoloquinoline derivative can be used as an inhibitor for pfap2-o5, a drug for inhibiting Plasmodium falciparum, or a drug for preventing or treating malaria.

The application discloses a polymer composite based on artemisinin modification, which is characterized in that the polymer composite comprises artemisinin compound modified organic silicon polyurethane and artemisinin compound modified organic silicon polyurea, and the mass ratio of the artemisinin compound modified organic silicon polyurethane and the artemisinin compound modified organic silicon polyurea is (2-1):(1-2). The application has the advantages of high hardness, good mechanical property, low elastic modulus, good stain removal effect, good adhesion, stable adhesion on a substrate and difficulty in falling off, excellent antibacterial effect, difficulty in hydrolysis in seawater or air moisture in use, good water resistance and long-term stability of the composite coating, so that the comprehensive performance of the coating is improved, and the application prospect of the environment-friendly marine antifouling coating is good.

This invention belongs to the field of pharmaceutical technology, specifically relating to a class of artemisinin derivatives, their preparation methods, and their use in the preparation of antitumor drugs. Cellular and animal experiments have shown that these compounds have outstanding antitumor effects.

The application relates to an application of artemisinin in tolerance DC cell culture, and provides a tolerance DC cell culture medium with artemisinin, which comprises a basic culture medium, cytokines and artemisinin, wherein the concentration of the artemisinin is 0.5-5 muM. The tolerance DC cell culture medium with artemisinin has reduced expression levels of co-stimulating molecules CD80, CD83, CD86 and HLA-DR, which indicates that the addition of artemisinin is beneficial to the tolerance DC cell culture.

This invention relates to the field of medical antibacterial technology, and in particular to a rare-earth artemisinin derivative organic salt, its preparation method, and its application, with the general formula [Art-COO]. n RE n+ In the formula, Art represents an artemisinin derivative, RE represents a rare earth ion, and n represents the valence of the rare earth ion; artemisinin derivatives include artesunate, and rare earth ions include La... 3+ Ce 3+ One of them. This invention utilizes the above-mentioned rare-earth artemisinin derivative organic salt, its preparation method, and its application. The obtained organic salt retains the peroxide bridge structure of artesunate, while the carboxylate group (-COO) is present. ‑ The stable existence of coordination bonds between rare earth ions and artesunate allows rare earth ions to synergistically enhance the antibacterial effect, significantly reducing the minimum inhibitory concentration against a variety of pathogens, and thus having important application value in the field of medical anti-infection.

The invention provides a transcription factor PfAP2-O5 inhibitor for Plasmodium falciparum, a pharmaceutical composition, and a drug for treating malaria resistant to artemisinin and an analog thereof. Disclosed in the present invention is new use of a hexahydroquinoline derivative or a pharmaceutically acceptable salt or hydrate thereof. The hexahydroquinoline derivative can inhibit the expression of an invasion gene pfap2-o5, block the invasion of Plasmodium falciparum into red blood cells, affect its growth and development, and achieve the effect of killing Plasmodium falciparum. Therefore, the hexahydroquinoline derivative can be used as an inhibitor for pfap2-o5, a drug for inhibiting Plasmodium falciparum, or a drug for preventing or treating malaria.

The invention relates to the technical field of medicines, and discloses an artemisinin external cream composition for burns and scalds and a preparation method thereof, the artemisinin external cream composition takes artemisinin as a core active component, and auxiliary materials such as an oil phase matrix, a water phase matrix, an emulsifier, a solubilizer, a transdermal enhancer, a stabilizer, a pH regulator and the like. During preparation, a thermal emulsification method is adopted, the oil-phase matrix and the emulsifier are heated and melted to form a uniform oil phase, the water-phase matrix, the humectant and the stabilizer are mixed and dissolved, artemisinin and the transdermal enhancer are pre-dissolved and then added into the oil phase, then the mixture and the water phase are emulsified at a high speed, the mixture is cooled and then the preservative is added for homogenization, and a stable cream system is formed. According to the invention, a peroxide bridge structure of artemisinin is utilized to remove active oxygen, and multiple effects of resisting inflammation, resisting oxidation, resisting bacteria, promoting repair and resisting scars are realized by regulating and controlling pathways of NF-kB, TGF-beta and the like; in addition, healing of deep second-degree scald wounds can be accelerated, scar formation is remarkably reduced, and the external cream composition with the wound sealing and moisturizing and multi-mechanism synergistic treatment effects is provided for clinic.

The invention discloses an artemisinin compound or a pharmaceutical salt thereof, the structure of which is shown as follows: the artemisinin compound provided by the invention has a brand new chemical structure, and in-vitro activity screening on solid tumor and hematologic tumor cells shows that most compounds show broad-spectrum and excellent in-vitro anti-tumor activity, so that the artemisinin compound or the pharmaceutical salt thereof can be applied to preparation of antitumor drugs. Wherein the antitumor activity of a plurality of compounds is superior to that of a marketed drug SAHA, and the compounds are expected to be developed into novel antitumor drugs. In addition, a plurality of compounds show in-vitro anti-malarial activity equivalent to that of artemisinin, and are expected to be developed into novel anti-malarial drugs.